# Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

> **NCT05549297** · PHASE3 · RECRUITING · sponsor: **Immunocore Ltd** · enrollment: 540 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Tebentafusp
- **DRUG:** Tebentafusp with Pembrolizumab
- **DRUG:** Investigators Choice

## Key facts

- **NCT ID:** NCT05549297
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-19
- **Primary completion:** 2028-03
- **Final completion:** 2028-07
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05549297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05549297, "Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05549297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*